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Abstract 
All sexually active youth, whether obese or normal weight, should be offered 
counselling regarding contraception and appropriate contraceptive methods. However, 
obese youth who are sexually active may be less likely than their normal weight peers to 
use contraceptives conectly. Methods of contraception for obese adolescents are 
reviewed in this discussion. Combined oral contraceptives (COCs) and the contraceptive 
patch have higher failure rates in obese versus normal weight females, though failure 
rates are lower than noted with barrier contraceptives. The risk for venous thrombosis is 
higher in obese youth on COCs. Progestin-only pills and the levonorgestrel intrauterine 
system appear to be safe and effective methods in obese females. Depot-
medroxyprogesterone acetate, intravaginal ring, and implants are also considered. 
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Introduction 
Sexually active adolescents whether chronically ill or not, should be offered 
contraception if they are not willing to accept abstinence (1-7). Adolescents who are obese 
are at risk for unwanted pregnancy with its well-known risks and thus, should also be offered 
safe and effective contraceptives. However, overweight or obese females are less likely to use 
contraception than their normal weight peers, despite their higher risk for pregnancy-related 
complications (8). This chapter reviews contraception in obese youth. In general, 
contraception is much safer than risks posed because of obesity and pregnancy. Effective 
methods that the clinician should consider include combined oral contraceptives, mini-pills, 
depo-medroxyprogesterone aceate, intravaginal ring, implantable contraception, and 
levonorgestrel intrauterine device (see table 1). Barrier methods are not generally effective in 
youth. 
Table 1. Contraceptive methods 
Abstinence 
Combined Oral Contraceptives (COCs) 
Contraceptive patch 
Mini-pills (Progestin-only pills; POPs) 
Emergency contraceptives 
Injectable Contraceptives 
Depo-Provera® (Depo-medroxy-progesterone acetate 
Lunelle® (estradiol cypionate and medroxyprogesterone acetate) 
Implants 
Norplant I (withdrawn from the US market in 2000) 
Implanon (one rod system with etonogestrel) 
Jadelle (Norplant II: two silastic rods with levonorgestrel) 
Intravaginal ring (NuvaRing) 
Intrauterine Devices 
Progestasert® IUD (with progesterone) 
ParaGard® (Copper T380A IUD) 
Mirena® (IUD with levonorgestrel) 
Vaginal barrier contraceptives 
Cervical cap (Prentif Cavity-rim®) 
Condoms (male) 
Contraceptive sponge (vaginal) 
Diaphragm 
Female condom (Reality®) 
Spermicides (vaginal) 
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Combined Oral Contraceptives (COCs) 
Females with obesity have some decreased efficacy with COCs due to higher basal 
metabolic rates, higher hepatic metabolism of enzymes, and drug sequestration that is higher 
in adipose tissue; however, efficacy is higher than noted with barrier methods (9-13). There 
are over 145 brands of combined oral contraceptives (COCs) used throughout the world, 
which generally contain both synthetic estrogen and synthetic progestin. In the United States, 
birth control pill brands are various combinations estrogen and progestin. The usual estrogen 
is ethinyl estradiol as the estrogen, though a few brands use mestranol. Various progestins are 
used including norgestrel, levonorgestrel, ethynodiol diacetate, norethindrone acetate, 
norethindrone, desogestrel, norgestimate, norethynodrel, drospirenone, and gestodene (not 
available in the US). The pill has been shown to be a safe and effective contraceptive for 
reproductive women - especially for those of the adolescent age group. Thus, motivate 
adolescent females who are obese can still be encouraged to use the COC despite the reported 
higher failure rates, mainly because of the overall efficacy of COCs and the known adverse 
pregnancy outcomes. 
Current recommendations are to begin with a monophasic pill, which has 30-35 meg of 
estrogen and 0.15 to 1.5 mg of progestin, or a triphasic pill. Triphasic pills are also 
recommended due to their low dose of estrogen and progestin. Careful monitoring and 
selection of patients for birth control pill use will reduce complications ofthe pill to a 
considerable extent. Contraindications to oral contraception are reviewed in table2. Sexually 
active youth who are on combined oral contraceptives are advised to use condoms as well. 
Table 2. WHO medical eligibility categories for OCPs. Used with permission (3) 
Category one (no restrictions) 
Antibiotics 
Benign breast disease 
Benign ovarian tumors 
Cervical ectropion 
Dysmenorrhea, 
Endometriosis 
Epilepsy 
Family history of breast cancer 
Gestational trophoblastic disease (benign or malignant) 
Headaches (mild) 
History of ectopic pregnancy or abortion (postabortion after first or second trimester), 
History of gestational diabetes 
Increased STD risk 
Iron deficiency anemia 
Irregular menstrual bleeding 
Obesity 
Ovarian or endometrial cancer 
Past pelvic surgery 
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Pelvic inflammatory disease 
Postpartum at or over 21 days 
Thyroid disorders (as hypo/hyperthyroidism, simple goiter) 
Varicose veins 
Various infections :malaria, tuberculosis, others) 
Sexually transmitted diseases 
Viral hepatitis carrier 
Categ01y two (caution) 
Cervical cancer 
Diabetes mellitus (uncomplicated) 
Headaches (severe and if they start after beginning OCPs) 
Hypertension at 140-159/100-109 mm Hg 
Major surgery without prolonged immobilization 
Migraine headaches without focal neurologic involvement. 
Patients who have a hard time taking the OCP correctly: 
drug or alchohol abuse 
mental retardation 
persistent history as poor OCP takers 
severe psychiatric disorders 
Sickle cell disease or sickle C disease 
Undiagnosed breast mass 
Categ01y three (Usually no OCP given) 
Gallbladder disease 
Lactating (6 weeks to 6 months), 
Less than 21 days postpartum 
Medications that interfere with OCP efficacy 
Undiagnosed abnmmal vaginal/uterine bleeding. 
Categ01y four (OCP contraindicated) 
Breast cancer 
Cerebrovascular accident (active or history) 
Complicated stmctural heart disease (with pulmonary hypertension, atrial fibrillation or history of subacute 
bacterial endocarditis) 
Coronary (or ischemic) heart disease (active or history) 
Deep vein thrombosis or pulmonary embolism (active of history) 
Diabetes mellitus (complicated with retinopathy, neuropathy, nephropathy) 
Headaches (including migraine headaches) with focal neurologic symptoms 
Hypertension (severe: (160+/110+ mm Hg or with vascular complications) 
Lactation under 6 weeks postpartum 
Liver disease (including liver cancer, benign hepatic adenoma, active viral hepatitis, severe cirrhosis) 
Pregnancy, complicated 
Surgery (involving the lower extremities and/or prolonged immobilization 
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Ortho Evra Patch 
The contraceptive patch provides contraceptive efficacy similar to COCs but may have 
an increased risk for cardiovascular complications due to delivery of increased hormonal 
levels in contrast to oral COCs (14). As noted with the birth control pill, obesity (weight over 
90 kg [ 198 pounds]) leads to reduced contraceptive efficacy, but still levels better than noted 
with barrier contraceptives (12,13,15,16). Dermatitis can occur as well with patch 
technology. Females with a history of skin allergy or exfoliative dermatological disorders 
may not be good candidates for the patch. There is also an increased incidence in breast 
symptoms, though most are reported to be mild or moderate ( 14, 17). Causes of increased risk 
of contraceptive failure include having the patch on over seven days, patch detachment, and 
failure to start a new patch after seven days of being off the patch. 
Contraindications to OCPs 
The World Health Organization has published a list of medical eligibility guidelines to 
provide clinicians with guidelines for COC use in those with various chronic illnesses that 
place users at increased risk of complications (see table 2) (18,19). Those in WHO Category 
I have no restrictions to OCP use, while those in Category 2 present with some increased 
risk, though the risks of pregnancy exceed them. Categmy 3 conditions have risks that are 
further increased, such that the pill is not used unless risks for pregnancy are even higher and 
no alternative contraceptive is available. Conditions found in Category 4 present risks that are 
so high that OCPs are not prescribed. 
Cardiovascular Complications 
Research has indicated an increased risk of cardiovascular complications in females on 
COCs (7 ,20,21 ). Obese females on bi1th control pills have an increased risk for pulmonary 
emboli, thrombophlebitis, and vascular thromboses. Some studies note a greater incidence of 
myocardial infarction and subarachnoid hemorrhage as well (21 ). An absolute OCP 
contraindication is a past history of venous thrombosis (VT) and the risk of VT is more 
significant for the adolescent or young adult than arterial thrombosis. Significant obesity is a 
VT risk factor and the risk is increased in obese COC users (12,13,22). 
Cardiovascular deaths from venous and aJterial complications in non-smoking females 
aged 20-24 years is 2-6 per million per year. There is a 3-6 fold increased risk factor for VT 
development in COC users and the risk for VT is higher with desogestrel versus 
levonorgestrel (7,20). The VT risk in the general population is 0.8 per 10,000 women per 
year, 3-4 for those on COCs, and 6-12 for females who are pregnant or postpartum 
(20,23 ,24). Most who develop venous thrombosis do not have identified VT risk factors. 
Table 3 lists screening questions to use when considering OCPs for contraception. In general, 
if there is no overt positive family history for VT, one does not need to screen for factor V 
Leiden or other prothrombotic mutations. 
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The pill should be stopped before situations arise requiring prolonged bed rest as with 
some surgeries. Hypertension and hyperlipidemia may be complications of obesity. Blood 
pressure should be regularly checked since it may rise in some patients.25 If there is a family 
or personal history of hyperlidemia, OCPs may still be prescribed if low-density lipoprotein 
(LDL)levels remain < 160 mg/dl and triglycerides < 250. COCs are not recommended for 
adolescents (obese or not) if they have congestive heart failure, cardiac shunts, or low output 
heart disorders.5,26. 
Table 3. Screening questions about personal/family history of thromboembolism 
1. Is there a history of blood clots in legs or lungs in close family members, including 
uncles and aunts? 
2. Have any of your close family members been in the hospital for leg/lung blood clots? 
3. Have you and/or close family members ever taking blood thinners? 
4. What were the circumstances that led to blood clot (s), as for example while as a 
result of traveling by airplane? 
Diabetes Mellitus 
Diabetes mellitus may be a complication of or occur incidental of obesity. Current 
evidence suggests that combined oral contraceptives are safe for obese females with well-
controlled diabetes mellitus types 1 and 2 (12). COCs do not worsen the metabolic status in 
diabetic females (12,13,27). Care is needed because of concern over worsening metabolic 
status due to progestins and increased risk for thromboembolic events due to estrogen (28). 
COCs should not be offered if they are in poor metabolic control or have hypertension, 
nephropathy, or retinopathy. Other contraceptive methods that are safe and effective in 
females with diabetes include progestin-only pills and the intrauterine device (IUD) (13). 
There may be an increase in recurrent, treatment-resistant vaginal yeast infections in diabetic 
youth with an IUD (28). The use of depo-medroxyprogesterone acetate or levonorgestrel 
implant may worsen the metabolic status in diabetic females. 
Migraine Headaches 
Caution is advised when prescribing the birth control pill to an individual with a history 
of migraine headaches and the COC should be stopped if the migraine aura or headache 
pattern worsen on COCs (1-4). If the individual has a history of severe migraines or 
migraines with prolonged auras (as with the hemiplegic or ophthalmoplegic types) the pill 
should not be given. If the migraine headache and/or the aura worsen while on the pill, it 
should be stopped immediately. Careful monitoring is advised when placing women with 
migraines on the pill. It is not known if obesity presents a greater risk for migraine-related 
cerebrovascular accidents that may be increased by the COCs or patch. 
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Table 4. Management of some oral contraceptive related problems 
Other Conditions 
PROBLEM 
Acne 
MANAGEMENT 
Anti-acne measures and 
medications 
Acute/Chronic Anti-fungal agents (as 
monilial fluconazole); persistent 
vaginitis infections: Look for underlying 
factors, as diabetes mellitus, other 
endocrinopathies, use of 
antibiotics, infected male genital 
tract, others. Oral nystatin may 
reduce gastrointestinal reservoir; 
use anti-fungal agents for a 
protracted period of treatment. 
Breakthrough 
bleeding 
Suspected 
pregnancy 
Weight gain 
or edema 
Usually a transient condition; 
ensure patient is taking the pill 
each day; higher estrogen pill or 
supplemental estrogen may help; 
evaluate for underlying pathology 
COCs are not teratogenic but 
should be stopped as soon as the 
pregnancy is identified. 
Use a lower estrogen pill 
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Females with active liver disease should not be placed on OCPs. The effect of obesity-
related NASH (nonalcoholic steatohepatitis) on COCs not clear at this time. Youth with 
obesity may be at risk for depression and no obesity-related complications with SSRis are 
reported. Tricyclic antidepressants can reduce estrogen levels with increased BTB but not 
reduced contraceptive efficaci St. John's wart is used to treat depression and can lead to 
increased break-through bleeding and anecdotal reports of reduced OC efficacy ( 1-4 ). Some 
females with obesity are at increased risk for fungal infections and some anti-fungal agents 
are potent hepatic enzyme inducers with resultant decreased contraceptive efficacy; these 
agents include griseofulvin, ketoconazole and itraconazole. Other drugs can interfere with 
contraceptive efficacy, such as rifampin. Table 4 lists management principles for 
miscellaneous side effects of COCs. 
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Progestin-Only Pills (POPs) (Mini-Pills) 
POPs contain 0.35 mg of norethindrone (Micronor®; Nor-Q.D®) and 0.075 mg of 
norgestrel (Ovrette®). Obesity may be associated with reduced contraceptive efficacy (13). 
POPs are typically used in those individuals having disorders where estrogen may be 
contraindicated - such as sickle cell anemia, cyanotic heart disease, severe hypertension, 
diabetes mellitus, and others (see table 2). Some clinicians have not recommended the mini-
pill for teenagers because of its increased pregnancy rate as well as frequent breakthrough 
bleeding and amenorrhea noted in some females on the mini-pill (1-4). POPs are avoided in 
those with a history of ectopic pregnancy and those taking certain medications (as 
anticonvulsants, griseofulvin and rifampin). There is no increase in VT in obese females on 
progestin-only pills ( 12, 13). 
Depot-Medroxyprogesterone Acetate (DMPA) 
The main injectable contraceptive available in the US is depomedroxy-progesterone 
acetate (Depo-Provera®). It is given in a dose of 150 mg intramuscularly every three months 
and DMPA has a better contraceptive efficacy than the COC with a failure rate of 0.3%. No 
decreased contraceptive efficacy is noted in obese females versus normal weight females 
(13). Its mechanism of action includes an induction of a low FSH/LH level, low LH surge, 
production of an atrophic endometrium, and thickening of the cervical mucus. Side effects 
include inegular menses, amenorrhea, acne, breast tenderness, weight gain (with bloating), 
decrease in bone density, decrease in high-density lipoprotein levels, and some behavioral 
changes such as irritability and depression. 
It is useful where a highly effective contraceptive is needed and where the side effects of 
an estrogen-type contraceptive must be avoided. Thus, it has been used for individuals with 
cyanotic heart disease, sickle-cell anemia, thrombophlebitis, and others. Internationally, 
psychotic and retarded individuals who are at risk for pregnancy have been prescribed this 
injectable contraceptive. It is considered to be a very effective hormonal contraceptive for 
obese females, despite the reported change in body composition towards fatness and central 
redistribution of fat following its use. 
Another injectable contraceptive, Lunelle® (5 mg estradiol cypionate and 25 mg 
medroxyprogesterone acetate [MPA/E2C]), was approved by the FDA in 2000. Estrogen is 
added to allow a better menstrual period rhythm than seen with Depo-Provera. Less weight 
gain is noted and overall adverse effects are similar to COCs (29). Lunelle® is given 
intramuscularly every 28-30 days and it has a high contraceptive efficacy rate (30). One study 
noted that there was a weight gain of 0.9 kg to 1.8 kg if the female weighed under 68 kg 
versus a weight gain of 1.4 to 3.6 kg if over 68 kilograms (30). There is no ovett 
contraindication in females with obesity. 
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Emergency Contraceptives 
Emergency contraceptives (EC) are among the most controversial and under prescribed 
contraceptive methods (seee table 5)(31 ). Obesity is not a contraindication to .use of ECs. 
Anti-emetics can be given to prevent the frequent occurrence of nausea and. emesis that 
occurs with high dose estrogen; thus, an antiemetic should be taken an hour before taking 
these pills. In 1999, the US Food and Drug Administration (FDA) approved of Plan B®, a 
progestin-only method with two tables of 0.75 mg of levonorgestrel. The first tablet is taken 
immediately and the second tablet is taken two hours later. Because Plan B® contains no 
estrogen, nausea and vomiting is uncommon and there is no need to obtain a pregnancy test 
before administation. Thus, Plan B may be better tolerated than those with estrogen (32). 
Though the official recommendation is that they must be used within three days of coitus, 
they may be effective in pregnancy prevention within five days. 
Table 5. Emergency contraceptives 
Ovral® : 2 tablets followed by 2 tables in 12 hours 
Lo/Ovral®, Nordette® or Levien® : 4 tabs and 4 more in 12 hours 
Plan B®: levonorgestrel, 0.75mg followed by 0.75 mg in 12 hours 
Preven® Emergency Contraceptive Kit 
Ovrette®: 20 tabs and 20 more in 12 hours 
TriPhasil® or Tri-Levlen® (yellow tabs only): 4 tabs, and 4 more in 12 hours 
NuvaRing® (Vaginal Ring) 
This is a soft, flexible, transparent vaginal ring made of a ethylene vinyl acetate 
copolymer; it has an outer diameter of 54 mm and a cross-section of 4 mm (2,4). There are 
two steroid reservoir cores that provide a daily hormonal release of 15 meg of ethinyl 
estradiol and 120 meg of etonogestrel (an active metabolite of desogestrel) (30,33). Side 
effects include extended withdrawal bleeding, vaginal discomfort, nausea, headache, 
nervousness, acne, breast tenderness, leukorrhea, reduced libido, and slight weight gain. 
There is an increased risk of thrombotic diseases (34). There is usually less irregular bleeding 
than seen with COCs. Extremely overt weight females may have trouble insetting the ring. 
Obesity itself does not effect the contraceptive efficacy of the NuvaRing and it is considered 
as one of the most effective hormonal contraceptive methods for obese females. 
Implanon® 
Norplant® was the first implantable contraceptive developed and was very effective as a 
contraceptive. It contains six silastic levonorgestrel-containing rods; however, it was 
withdrawn from the United States market in 2000 (2,4). The Jadelle® implant (Norplant II) 
contains two silastic rods with levonorgestrel and Implanon® contains one rod (vinyl 
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ethylene acetate polymer) with etonogestrel (7,35). Both Jadelle® and Implanon® are 
approved by the FDA for three years and are not contraindicated in obesity, though both may 
induce some weight gain. Though obese females have been found to have lower serum 
etonogestrellevels, there is no reduced efficacy noted with Implanonin obese female (13,36). 
Intrauterine Device (IUD) 
There are three IUDs which currently are used in the United States: Progestasert IUD®, 
the ParaGard® (Copper T380A) and the Mirena IUD (2,4,37-39). Previous controversial IUD 
links with pelvic inflammatory disease (PID) have limited its application to adolescents. 
However, the IUD is an excellent contraceptive method with no contraindication in obese 
women. The Mirena® IUD (Levonorgestrel-containing IUD; LNG-IUD) was FDA-approved 
in 2001 for five years and contraindications are active PID, prosthetic heart valves, history of 
subacute bacterial endocarditis, and distorted uterine cavity. The most common side effect is 
menstrual bleeding; there is increased bleeding and spotting during the first 3-6 months after 
insertion that usually decreases after this time. Obese females have an increased incidence of 
dysfunctional uterine bleeding and endometrial hyperplasia, making the Mirena IUD a good 
contraceptive choice for obese females needing contraception (12). No reduced contraceptive 
efficacy has been noted because of obesity (13,40). In diabetic patients, an increase in vaginal 
yeast infections should be taken under consideration. 
Conclusions 
Contraceptive efficacy is reduced in obese females on the combined oral contraceptive 
and the contraceptive patch; however, the efficacy is still above that noted with barrier 
contraceptives. COCs are safe with obese females with diabetes mellitus if they are in good 
control and do not have nephropathy, retinopathy, neuropathy, or hypettension. Progestin-
only pills are safe in obese females but decreased contraceptive efficacy is noted in all 
females on this contraceptive method. Obesity is not a contraindication to use of depo-
medroxyprogesterone acetate, IUD, and intravaginal ring. The mini-pill and levonorgestrel 
IUD may be the safest for obese females needing contraception (12). 
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